FOX CHASE CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1904-01-01

Employees: -

Market Cap: -

Website: http://www.foxchase.org

Clinical Trials

Heavy Metal Exposure in Predicting Peripheral Neuropathy in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy

Completed

Conditions: Stage IIIA Breast Cancer
Male Breast Cancer
Neurotoxicity
Stage II Breast Cancer
Peripheral Neuropathy
Stage IA Breast Cancer
Stage IB Breast Cancer
Stage IIIB Breast Cancer
Stage IIIC Breast Cancer

Interventions: Other: laboratory biomarker analysis
Other: questionnaire administration

First Posted Date: 2013-11-13

Last Posted Date: 2017-06-15

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 115

Registration Number: NCT01982591

Locations: 🇺🇸
Paoli Memorial Hospital, Paoli, Pennsylvania, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1

Terminated

Conditions: Recurrent Primary Peritoneal Cavity Cancer
Recurrent Fallopian Tube Cancer
Recurrent Ovarian Epithelial Cancer

Interventions: Drug: paclitaxel
Drug: ganetespib
Other: laboratory biomarker analysis

First Posted Date: 2013-10-16

Last Posted Date: 2024-03-26

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 12

Registration Number: NCT01962948

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Trial of Print Messages to Support the Role of Partners in Promoting Provider Discussions About Prostate Cancer Screening Among AA Men

Not Applicable

Completed

Conditions: Prostate Cancer

Interventions: Behavioral: CDC brochure only condition
Behavioral: Partner and CDC brochure condition

First Posted Date: 2013-09-09

Last Posted Date: 2013-09-09

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 231

Registration Number: NCT01937585

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Telomere Length in Predicting Toxicity in Older Patients With Stage III-IV Colorectal Cancer Undergoing Chemotherapy

Terminated

Conditions: Mucinous Adenocarcinoma of the Colon
Mucinous Adenocarcinoma of the Rectum
Signet Ring Adenocarcinoma of the Colon
Signet Ring Adenocarcinoma of the Rectum
Stage IIIA Colon Cancer
Stage IIIA Rectal Cancer
Stage IIIB Colon Cancer
Stage IIIB Rectal Cancer
Stage IIIC Colon Cancer
Stage IIIC Rectal Cancer

Interventions: Other: cytology specimen collection procedure
Other: laboratory biomarker analysis
Other: questionnaire administration

First Posted Date: 2013-09-04

Last Posted Date: 2018-02-07

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 6

Registration Number: NCT01934179

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Quinacrine-Capecitabine Combinatorial Therapy for Advanced Stage Colorectal Adenocarcinoma

Phase 1

Terminated

Conditions: Colorectal Adenocarcinoma

Interventions: Drug: Quinacrine and Capecitabine

First Posted Date: 2013-05-01

Last Posted Date: 2021-03-25

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 19

Registration Number: NCT01844076

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Study to Evaluate NA-NOSE for Monitoring and Detecting Recurrence in Early Stage Lung Cancer

Not Applicable

Completed

Conditions: Stage IB Non-small Cell Lung Cancer
Stage IIA Non-small Cell Lung Cancer
Stage IIB Non-small Cell Lung Cancer
Stage IA Non-small Cell Lung Cancer

Interventions: Procedure: breath test
Other: laboratory biomarker analysis

First Posted Date: 2013-04-25

Last Posted Date: 2023-03-13

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 41

Registration Number: NCT01840150

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or May Not be Removed by Surgery

Phase 1

Terminated

Conditions: Acinar Cell Adenocarcinoma of the Pancreas
Stage IIB Pancreatic Cancer
Duct Cell Adenocarcinoma of the Pancreas
Stage III Pancreatic Cancer

Interventions: Drug: gemcitabine hydrochloride
Radiation: hyperfractionated radiation therapy
Radiation: intensity-modulated radiation therapy
Radiation: radiosurgery
Procedure: diffusion-weighted magnetic resonance imaging

First Posted Date: 2012-12-03

Last Posted Date: 2019-07-29

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 6

Registration Number: NCT01739439

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care

Not Applicable

Completed

Conditions: Signet Ring Adenocarcinoma of the Colon
Stage IIB Colon Cancer
Stage IIC Colon Cancer
Stage IIC Rectal Cancer
Stage IIIA Colon Cancer
Stage IB Non-small Cell Lung Cancer
Stage IIB Non-small Cell Lung Cancer
Stage IIB Rectal Cancer
Stage IIIB Colon Cancer
Stage IIIB Rectal Cancer

Interventions: Other: educational intervention
Other: medical chart review

First Posted Date: 2012-11-14

Last Posted Date: 2017-04-06

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 1440

Registration Number: NCT01726296

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer

Phase 1

Completed

Conditions: Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
Recurrent Basal Cell Carcinoma of the Lip
Recurrent Colon Cancer
Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity
Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity
Recurrent Lymphoepithelioma of the Nasopharynx
Recurrent Lymphoepithelioma of the Oropharynx
Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity
Recurrent Mucoepidermoid Carcinoma of the Oral Cavity

Interventions: Drug: everolimus
Biological: cetuximab
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2012-07-11

Last Posted Date: 2012-07-11

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 12

Registration Number: NCT01637194

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer

Phase 2

Terminated

Conditions: Stage II Bladder Cancer
Stage III Bladder Cancer
Proximal Urethral Cancer
Squamous Cell Carcinoma of the Bladder
Distal Urethral Cancer
Urethral Cancer Associated With Invasive Bladder Cancer

Interventions: Drug: gemcitabine hydrochloride
Drug: cisplatin
Procedure: therapeutic conventional surgery
Other: laboratory biomarker analysis

First Posted Date: 2012-06-05

Last Posted Date: 2019-07-29

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 32

Registration Number: NCT01611662

Locations: 🇺🇸
Thomas Jefferson University, Kimmel Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Home Terms & Conditions Privacy Policy